People · Operator
Named in public records as an officer, director or promoter · active 2009–2020 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Vir Biotechnology, Inc. | — | Biotechnology | Series D+ | $348.4M | $1.3B | 2018 |
| Syros Pharmaceuticals, Inc. | — | Biotechnology | Series D+ | $296.1M | $2.6B | 2018 |
| Akouos, Inc. | — | Biotechnology | Series D+ | $137.7M | $4.3B | 2020 |
| Proclara Biosciences, Inc. | — | Biotechnology | Series C | $76.8M | $283.6M | 2011 |
| Avila Therapeutics Inc | — | Biotechnology | Series B | $45.0M | $893.0M | 2009 |
| Nimbus Discovery, LLC | — | Pharmaceuticals | Seed | $5.0M | $57.1M | 2010 |
Vicki Sato at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Vicki Sato on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Robert Nelsen | 2 | 22 |
| Amir Nashat | 2 | 14 |
| Bruce Booth | 2 | 12 |
| Daniel Lynch | 2 | 7 |
| Philip Sharp | 2 | 2 |
| Kristina Burow | 1 | 16 |
| Ed Mathers | 1 | 11 |
| Srinivas Akkaraju | 1 | 10 |
| Kush Parmar | 1 | 10 |
| Robert More | 1 | 7 |
| Chris Smith | 1 | 7 |
| Heather Preston | 1 | 6 |
| Douglas Cole | 1 | 5 |
| Ramy Farid | 1 | 5 |
| Noubar B Afeyan | 1 | 5 |
| Nick Leschly | 1 | 5 |
| Raj Parekh | 1 | 5 |
| Katrine Bosley | 1 | 4 |
| Stephane Bancel | 1 | 4 |
| Henry Skinner | 1 | 4 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.